4.7 Article

Outcome of rare primary malignant bone sarcoma (RPMBS) treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-BOSS)

Journal

CANCER
Volume -, Issue -, Pages -

Publisher

WILEY
DOI: 10.1002/cncr.34964

Keywords

angiosarcoma; bone sarcoma; chemotherapy; fibrosarcoma; leiomyosarcoma; multimodality treatment; nonosteosarcoma malignant bone tumors; rare primary malignant bone sarcoma (RPMBS); ultra-rare sarcoma; undifferentiated pleomorphic sarcoma

Categories

Ask authors/readers for more resources

This study evaluated the treatment outcomes of European RPMBS patients, including local control and overall survival. Patients with localized disease and achieved surgical complete remission had higher 5-year overall survival rates. Therefore, using an osteosarcoma-like chemotherapy regimen may be a reasonable choice for RPMBS patients.
BackgroundRare primary malignant bone sarcomas (RPMBS) account for 5%-10% of primary high-grade bone tumors and represent a major treatment challenge. The outcome of patients with RPMBS enrolled in the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S) is presented. MethodsInclusion criteria were as follows: age from 41 to 65 years and a diagnosis of high-grade spindle cell, pleomorphic, or vascular RPMBS. The chemotherapy regimen included doxorubicin 60 mg/m(2), ifosfamide 9 g/m(2), and cisplatin 90 mg/m(2); postoperative methotrexate 8 g/m(2) was added in case of a poor histologic response. Version 2.0 of the Common Terminology Criteria for Adverse Events, Kaplan-Meier curves, log-rank tests, and univariate Cox regression models were used. ResultsIn total, 113 patients were evaluable for analysis. The median patient age was 52 years (range, 40-66 years), and 67 patients were men. Eighty-eight tumors were categorized as undifferentiated pleomorphic sarcomas (UPS), 20 were categorized as leiomyosarcomas, three were categorized as fibrosarcomas, and two were categorized as angiosarcomas. Eighty-three of 113 tumors were located in the extremities. Ninety-five of 113 patients presented with no evidence of metastases. After a median follow-up of 6.8 years (interquartile range [IQR], 3.5-9.8 years), the 5-year overall survival rate for patients with localized disease was 68.4% (IQR, 56.9%-77.5%), and it was 71.7% (IQR, 58.1%-81.6%) for patients with UPS and 54.9% (IQR, 29.5%-74.5%) for patients with leiomyosarcoma. Grade III-IV hematologic toxicity was reported in 81% patients; 23% had grade II-III neurotoxicity, and 37.5% had grade I-II nephrotoxicity. Five-year overall survival was significantly better for patients with localized disease, for patients who obtained surgical complete remission, and when the primary tumor was located in the extremities. ConclusionsThe survival of patients who had RPMBS in the current series was similar to that of age-matched patients who had high-grade osteosarcoma treated according to the same protocol. An osteosarcoma-like chemotherapy may be proposed in patients who have RPMBS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available